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Abstract
Background: Evidence relating childhood cancer to high birthweight is derived primarily from registry and case–
control studies. We aimed to investigate this association, exploring the potential modifying roles of age at diagno-
sis and maternal anthropometrics, using prospectively collected data from the International Childhood Cancer
Cohort Consortium.
Methods: We pooled data on infant and parental characteristics and cancer incidence from six geographically and
temporally diverse member cohorts [the Avon Longitudinal Study of Parents and Children (UK), the Collaborative
Perinatal Project (USA), the Danish National Birth Cohort (Denmark), the Jerusalem Perinatal Study (Israel), the
Norwegian Mother and Child Cohort Study (Norway), and the Tasmanian Infant Health Survey (Australia)].
Birthweight metrics included a continuous measure, deciles, and categories (≥4.0 vs. <4.0 kilogram). Childhood
cancer (377 cases diagnosed prior to age 15 years) risk was analysed by type (all sites, leukaemia, acute
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lymphoblastic leukaemia, and non-leukaemia) and age at diagnosis. We estimated hazard ratios (HR) and 95%
confidence intervals (CI) from Cox proportional hazards models stratified by cohort.
Results: A linear relationship was noted for each kilogram increment in birthweight adjusted for gender and
gestational age for all cancers [HR = 1.26; 95% CI 1.02, 1.54]. Similar trends were observed for leukaemia. There
were no significant interactions with maternal pre-pregnancy overweight or pregnancy weight gain. Birthweight
≥4.0 kg was associated with non-leukaemia cancer among children diagnosed at age ≥3 years [HR = 1.62; 95% CI
1.06, 2.46], but not at younger ages [HR = 0.7; 95% CI 0.45, 1.24, P for difference = 0.02].
Conclusion: Childhood cancer incidence rises with increasing birthweight. In older children, cancers other than
leukaemia are particularly related to high birthweight. Maternal adiposity, currently widespread, was not demon-
strated to substantially modify these associations. Common factors underlying foetal growth and carcinogenesis
need to be further explored.
Keywords: Childhood cancer, leukemia, cohort studies, pooled analysis.
Over 50 years ago, MacMahon and Newill1 suggested
that birthweight may be linked to childhood cancer
risk. This putative association was subsequently exam-
ined in diverse geographical settings, mainly in case–
control studies. Early studies focused on childhood
cancer mortality1–3 while later investigations, summa-
rised in two meta-analyses,4,5 primarily addressed the
association between birthweight and the incidence
of acute leukaemia, or its main subtypes, acute
lymphoblastic (ALL), and acute myeloid leukaemia
(AML). Evidence from these studies supports an
overall weakly to moderately increased risk of ALL
among children with high birthweight (generally
defined as ≥4.0 kg), or a linear association with each
kilogram birthweight increment,4,5 although some
studies have had null or negative findings.,6–8 and the
influence of birthweight on AML is less consistent.
Evidence regarding non-leukaemia cancers points
to higher risks of renal (notably Wilms), embryonal
and specific Central Nervous System (CNS)
tumours9–11 with high birthweight. For some cancers,
non-linear models best describe the association with
birthweight and, for hepatic tumours (notably
hepatoblastoma), a negative association has been
observed.11
More recent research has emphasised the role of
accelerated foetal growth (taking into account factors
such as gestational age (GA)), rather than birthweight
per se, as a determinant of childhood cancer.12–16
Among these studies are recent pooled analyses of
case–control studies.11,17,18 Adjustment for GA may
change both the magnitude and the precision of rela-
tive risk estimates.11
Fetal growth is determined by both environmental
and genetic factors19 and is influenced by maternal
attributes, notably height, parity, diabetes and other
metabolic factors, smoking, socioeconomic status, and
ethnicity.20,21 Moreover, maternal pre-pregnancy over-
weight22,23 and excess pregnancy weight gain23 are
increasingly recognised determinants of large-for-GA
babies. Current maternal obesity trends portend an
increased proportion of these infants,24 and a possible
concomitant rise in metabolic and cardiovascular mor-
bidity for the offspring.25 However, the potential con-
sequences of maternal adiposity for childhood cancer
have rarely been considered.26 In contrast to a wealth
of information regarding determinants of foetal
growth, risk factors for childhood cancer are largely
unknown. Controversy remains as to whether the
association between birthweight and childhood
cancer varies, for example, by age at diagnosis.
The International Childhood Cancer Cohort Consor-
tium (I4C)27 provides a platform to examine cancer
risk factors using pooled data collected prior to
disease onset. This, combined with the prospect of
evaluating the contribution of a rich set of covariates,
affords an opportunity to obtain a deeper and less
biased understanding of the association between
birthweight and childhood cancer. Our aims were to
re-examine this association, taking into account GA
and other covariates, and to explore the potential
modifying effects of age at diagnosis and maternal
anthropometric measures.
Methods
The I4C
I4C was established in 2005 to address the lack of pro-
spective, adequately powered studies investigating
the aetiology of childhood cancer. The initial collabo-
ration involved 11 international birth/infant cohorts
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ranging from ∼11 000 to 100 000 participants at various
stages of recruitment or follow-up.27 Additional
cohorts have since joined. This report involves the
pooling of data from (alphabetically): the Avon Longi-
tudinal Study of Parents and Children (ALSPAC, UK),
the Collaborative Perinatal Project (CPP, USA), the
Danish National Birth Cohort (DNBC, Denmark), the
Jerusalem Perinatal Study (JPS, Israel), the Norwegian
Mother and Child Cohort Study (MoBa, Norway), and
the Tasmanian Infant Health Survey (TIHS, Australia).
Data from all cohorts were transferred to the I4C
International Data Coordinating Center (IDCC) at the
Murdoch Childrens Research Institute (Australia).
Harmonisation and pooling of data from the six
cohorts was undertaken at the I4C IDCC and involved
creating variables that would allow for amalgamation
of the available data across all six cohorts (Please see
supporting information Appendix S1 for description
of participating cohorts, references, ethical issues, and
harmonisation strategies).
Study design and population
We performed a pooled cohort study, identifying and
including all cancer cases from 380 000 livebirths in
the six participating cohorts. The dataset includes all
livebirths for ALSPAC, CPP, and TIHS. As per Con-
sortium agreements with the I4C, a random 10%
sample of non-cases from MoBa and DNBC rather
than the entire cohorts were included. Offspring from
the JPS cohort were included if their GA was recorded
(from mothers’ pre- or postpartum interviews), com-
prising all those born 1974–1976, and a subset born
1964–1973 (total n = 20 944). The pooled dataset thus
comprises 112 781 livebirths, after excluding multiple
births (due to their high rate of low birthweight)28 and
children with Down syndrome (due to their particu-
larly high risk of childhood leukaemia)29 (Table 1).
Cancer ascertainment
Childhood cancer (diagnosed <15 years of age) was
ascertained by linkage to national registries for
ALSPAC, DNBC, JPS, and MoBa. For TIHS, linkage
was with the Tasmanian Cancer Registry. Cancer cases
for CPP were identified via examination of diagnostic
summaries and other indirect methods such as identi-
fying children reported in previous investigations of
cancer and x-ray exposure, and manually reviewing
death records for children with birthweight ≥1500 g
who survived the first week of life. Each potential
cancer diagnosis was reviewed by two board-certified
paediatricians.
Tumours were classified into four main groups
based on the International Classification of Diseases
(ICD)-0 Third Edition:30 all cancers (C-code 42), leu-
kaemia (morphology codes 9800–9941), ALL (codes
9820–9827, 9850), and non-leukaemia cancer (C-code
42, excluding 9800–9991). Small numbers of AML and
specific solid tumours across the six cohorts precluded
analysis of individual cancer subtypes besides ALL.
Birthweight metrics
Birthweight was analysed using three approaches:
first, dichotomised as ≥4.0 kg vs. <4.0 kg. The second
approach took into account differing birthweight dis-
tributions across populations and time. For example
the 90th percentile of birthweight was as follows:
ALSPAC: 4129, CPP: 3827, DNBC: 4320, JPS: 3880,
MoBa: 4260, and TIHS: 4030 g. To explore whether the
heaviest newborns in each cohort, regardless of abso-
lute weight, were at higher risk of cancer, we chose
membership in the top decile as the ‘exposed’ group
while the lower 90% of children comprised the refer-
ence group. Finally, birthweight was assessed as a con-
tinuous variable in 0.5 and 1.0 kg increments.
Covariates and potential confounders
A number of variables previously shown to be associ-
ated with birthweight or childhood cancer were
assessed as potential confounders or effect modifiers.
These included:
1. Maternal factors: age at time of index child’s birth
(years); married/cohabitating at time of enrolment
(yes/no); at least 12 years of education completed
(yes/no); any smoking during pregnancy (yes/no);
exposure to any smoking at home during preg-
nancy (yes/no); parity – defined as the number of
previous livebirths (for all cohorts except ALSPAC
and DNBC that includes number of previous preg-
nancies and stillbirths), grouped as 0/1–2/≥ 3;
pre-existing or gestational diabetes (yes/no); pre-
pregnancy body mass index [BMI = weight (kg)/
height (m2)]; and total pregnancy weight gain (kg).
2 Factors relating to the index child: GA (weeks),
determined by date of last menstrual period (or
ultrasound in a subgroup from MoBa and ALSPAC);
sex; first born (yes/no), birth length (cm); placental
weight (g); and age at diagnosis of primary cancer
(years).
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Table 1. Descriptive maternal, paternal, and offspring characteristics of the six I4C member cohorts included in the pooled dataset
ALSPAC CPP DNBC JPS MoBa TIHS Total
Recruitment years 1991–1992 1959–1965 1996–2002 1964–1976 1999–2009 1987–1995 1959–2007
Singleton livebirths with no DS 13 664 50 342 8603 20 313 10 497 9 362 112 781
Years of follow-up 14.9 5.6 11 15 4.4 14.7 9.9
Mean (range) (0.5–15) (0.0–8.0) (8.3–14.0) (15.0–15.0) (0.5–10.1) (12.7–15.0) (0.0–15.0)
Maternal age (years)
Mean ± SD 28.0 ± 5.0 24.1 ± 5.9 30.5 ± 4.2 27.3 ± 5.4 30.2 ± 4.6 23.6 ± 4.4 26.2 ± 5.9
Missing (%) 0 (0.0) 0 (0.0) 2 (0.02) 77 (3.8) 10 (0.1) 0 (0.0) 89 (0.08)
Married or cohabitating, n (%) 9 588 (70.2)a 38 658 (76.8) 8094 (94.1) 20 142 (99.2) 9 591 (91.4) 7 318 (78.2) 93 389 (82.8)
Missing (%) 861 (6.3) 2 (0.01) 359 (4.2) 114 (0.6) 591 (5.6) 32 (0.3) 1 590 (1.7)
Mother completed 12 or more years of
education, n (%)
4 286 (31.4)d 20 767 (41.3) 4097 (47.6) 9 866 (48.6) 6 246 (59.5) 1 690 (18.0) 46 952 (41.6)
Missing (%) 1 536 (11.2) 122 (0.24) 2349 (27.3) 358 (1.8) 595 (5.7) 21 (0.2) 4 981 (4.4)
Maternal prenatal smoking, n (%) 3 530 (25.8) 23 269 (46.2) 2 193 (25.5) 2 568 (12.6) 925 (8.8) 5 023 (53.6) 37 508 (33.3)
Missing (%) 1 639 (12.0) 263 (0.5) 9 (0.1) 193 (1.0) 2 295 (21.9) 16 (0.2) 4 415 (3.9)
Passive smoking at home, prenatal, n (%)b 5 362 (39.2) n/a 5584 (64.9) 7 438 (36.6) 770 (7.3) 5 242 (56.0) 24 396 (39.1)
Missing (%) 1 859 (13.6) 3005 (34.9) 3 828 (18.8) 1 397 (13.3) 20 (0.2) 10 109 (16.2)
Parity, n (%)
No prior livebirth 1 377 (10.1) 1 142 (2.3) n/a n/a 1 239 (11.8) n/a 3 758 (3.6)
No prior pregnancy 4 263 (31.2) 14 187 (28.2) 3861 (44.9) 6 249 (30.8) 3 229 (30.8) 31 789 (30.7)
1–2 6 090 (44.6) 19 768 (39.3) 4117 (47.9) 8 713 (42.9) 4 960 (47.2) 43 648 (42.2)
≥3 733 (5.4) 15 191 (30.2) 261 (3.0) 5 279 (26.0) 292 (2.8) 21 753 (21.0)
Missing (%) 1 201 (8.8) 54 (0.1) 364 (4.2) 76 (0.4) 777 (7.4) 2 472 (2.4)
Maternal pre-pregnancy BMI, kg/m2
Mean ± SD 22.9 ± 3.8 22.7 ± 4.3 23.6 ± 4.4 22.1 ± 3.1 24.0 ± 4.2 23.2 ± 4.8 22.9 ± 4.1
Missing (%) 2 396 (17.5) 4 372 (8.7) 493 (5.7) 6 010 (29.6) 835 (7.9) 3 113 (33.2) 17 219 (15.3)
Maternal pregnancy weight gain, kg
Mean ± SD 12.5 ± 4.7 9.8 ± 4.8 15.1 ± 5.8 11.2 ± 4.3 14.9 ± 5.8 13.9 ± 6.4 11.5 ± 5.4
Missing (%) 1 573 (11.5) 3 816 (7.6) 1947 (22.6) 5 679 (27.6) 2 550 (24.3) 1 704 (18.2) 17 269 (15.3)
Maternal height, cm
Mean ± SD 163.9 ± 6.7 160.9 ± 6.9 168.8 ± 6.0 162.0 ± 6.0 168.0 ± 5.9 162.2 ± 7.3 162.9 ± 7.2
Missing (%) 1 717 (12.6) 3 740 (7.4) 361 (4.2) 4 678 (23.0) 660 (6.3) 2 452 (26.2) 13 608 (12.1)
Maternal DM, n (%) n/a
Pre-existing 442 (3.2)c 264 (0.5) 25 (0.3) 36 (0.2) 55 (0.5) 882 (0.8)
Gestational 55 (0.4) 127 (0.2) 139 (1.6) 110 (0.5) 85 (0.8) 516 (0.5)
Missing (%) 1 585 (11.6) 129 (0.3) 0 (0.0) 90 (0.4) 0 (0.0) 1 804 (1.7)
Any previous miscarriage, n (%) 2 719 (19.9) 9 031 (17.9) 1563 (18.2) 4 416 (21.7) 1 925 (18.3) n/a 19 654 (19.0)
Missing (%) 961 (7.0) 0 (0) 365 (4.2) 104 (0.5) 777 (7.4) 2 207 (2.1)
Paternal age (years)
Mean ± SD 30.7 ± 5.8 28.2 ± 7.0 32.8 ± 5.1 30.9 ± 6.5 32.7 ± 5.3 26.5 ± 5.6 29.8 ± 6.6
Missing (%) 2 269 (16.6) 12 795 (25.4) 123 (1.4) 654 (3.2) 47 (0.4) 215 (2.3) 16 103 (14.3)
Father completed at least 12 years of
education, n (%)
5 151 (37.7)d 19 209 (38.2) 2700 (31.4) 10 828 (53.3) 4 782 (45.6) 1 624 (17.3) 44 294 (39.3)
Missing (%) 2 012 (14.7) 9 651 (19.2) 2541 (29.5) 418 (2.1) 883 (8.4) 865 (9.2) 16 370 (14.5)
Gestational age, weeks
Mean ± SD 39.5 ± 1.9 39.4 ± 3.1 40.1 ± 1.7 39.7 ± 2.2 39.5 ± 1.8 38.8 ± 2.6 39.5 ± 2.6
Missing (%) 0 (0.0) 329 (0.6) 0 (0.0) 0 (0.0) 47 (0.4) 29 (0.3) 405 (0.4)
Gender, male n (%) 7 052 (51.6) 25 461 (50.6) 4367 (50.8) 10 485 (51.6) 5 274 (50.2) 6 673 (71.3) 59 312 (52.6)
Missing (%) 2 (0.01) 81 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 93 (0.1)
Birthweight, grams
Mean ± SD 3 410 ± 551 3 177 ± 531 3599 ± 549 3 260 ± 508 3 604 ± 562 3 195 ± 751 3 293 ± 577
Missing (%) 172 (1.3) 192 (0.4) 32 (0.4) 52 (0.3) 20 (0.2) 0 (0.0) 468 (0.4)
Placental weight, grams
Mean ± SD 652 ± 138 437 ± 94 663 ± 148 n/a 676 ± 149 613 ± 161 531 ± 163
Missing (%) 8 103 (59.3) 7 864 (15.6) 288 (3.3) 325 (3.1) 149 (1.6) 16 729 (18.1)
First born, n (%) 5 500 (40.2) 14 187 (28.2) 3861 (44.9) 6 248 (30.8) 4 468 (42.6) 44 387 (46.9) 38 651 (34.3)
Missing (%) 1 090 (8.0) 54 (0.1) 364 (4.2) 76 (0.4) 777 (7.4) 11 (0.1) 2 372 (2.1)
Length at birth, cm
Mean ± SD 50.7 ± 2.4 49.9 ± 2.7 52.3 ± 2.5 n/a 50.4 ± 2.4 48.8 ± 3.4 50.2 ± 2.9
Missing (%) 3 399 (24.9) 1 515 (3.0) 81 (0.9) 387 (3.7) 221 (2.4) 5 603 (6.1)
ALSPAC = the Avon Longitudinal Study of Parents and Children (UK); CPP = the Collaborative Perinatal Project (USA); DNBC = the Danish National Birth
Cohort (Denmark); DS = Down syndrome; JPS = the Jerusalem Perinatal Study (Israel); MoBa = the Norwegian Mother and Child Cohort Study (Norway);
n/a = data not collected/provided; TIHS = the Tasmanian Infant Health Survey (Australia).
aConcerned marriage only.
bPassive smoking defined as any exposure to smoke at home by partner or others living in the home.
cIncludes glycosuria.
dEducational qualifications obtained were used as a proxy – but by law the school leaving age was 16 at the earliest.
Note that if a subject characteristic was n/a for a particular cohort, then the percentage in the ‘Total’ column is based on total number of observations
without including that cohort in the summary statistic.
338 O. Paltiel et al.
© 2015 The Authors. Paediatric and Perinatal Epidemiology published by John Wiley & Sons Ltd
Paediatric and Perinatal Epidemiology, 2015, 29, 335–345
3 Paternal factors: age at time of index child’s birth
(years), and completion of at least 12 years of educa-
tion (yes/no).
Follow-up time
Children in the ALSPAC and JPS cohorts were fol-
lowed to at least 15 years of age, or censored at date
of death. Follow-up of children in DNBC and MoBa
is ongoing. Children within these cohorts without
cancer are assumed to have been followed to the point
of last linkage to their national registries: 1 September
2011 and 31 December 2009, respectively. For TIHS,
in the absence of systematic follow-up of cohort
members, non-cases were deemed to be followed to
the last date of diagnosis of a case in the Tasmanian
Cancer Registry (28 September 2008), when the
youngest child was aged 12.73 years. Follow-up time
for the CPP was calculated as the number of months
from date of birth (or age 1 week) to the last recorded
visit, for a maximum of 8 years.
Missing data
Missing covariate data among the cohorts ranged from
0% to nearly 40% (see Table 1). In order to construct
multivariable models with maximal sets of covariates,
we used chained multiple imputation to impute 20
complete datasets.31 Cox regression was performed
separately on each imputed dataset and the results
pooled into a single multiple imputation result. We
used truncated linear regression to impute missing
continuous variables (paternal age, maternal height,
pregnancy weight gain, and pre-pregnancy BMI)
where the imputations are limited to lower and upper
boundaries set at the minimum and maximum values
of non-missing observations. Logistic regression was
used to impute missing dichotomous variables (first
born and maternal smoking). Variables used to
impute missing data were maternal age, GA,
birthweight, sex of child, and cohort.
Statistical analysis
We report hazard ratios (HR) and 95% confidence
intervals (CI) from Cox proportional hazards regres-
sion models. All models were stratified by cohort.
Model 1 was unadjusted (birthweight was the only
independent variable). Model 2 adjusted for GA and
child’s sex. Model 3 was a parsimonious multivariable
model adjusted for GA, child’s sex, as well as
different combinations of covariates for each cancer
outcome, chosen as follows:
Starting with all confounders in the model, we
removed variables one at a time (beginning with the
variable with the largest P-value, so long as that vari-
able no longer changed the coefficients for
birthweight or the other covariates in the model by
>15% in either direction) using the multiple imputa-
tion dataset. Once removed, a variable could not
re-enter the model.
Schoenfeld residuals were used to assess the pro-
portional hazard assumption with all covariates
entered into the model, first, on the original data con-
taining missing observations and, second, after imput-
ing the missing data. Proportionality assumptions
were met in both.32 We assessed the linearity of con-
tinuous variables in the log-hazard using the method
of fractional polynomials.33 Paternal age, determined
to be non-linear, was transformed to a quadratic
expression.
To assess the possibility of effect modification by
maternal anthropometric measurements, we intro-
duced interaction terms of birthweight × maternal
pre-pregnancy BMI using a cut-off of normal or
underweight (<25 kg/m2) vs. overweight (≥25 kg/
m2).34 In separate models, we introduced an interac-
tion term of birthweight × pregnancy weight gain,
dichotomised according to the Institute of Medicine
recommendation (based on a healthy BMI) of ≤16 kg
vs. >16 kg.35
To determine whether the birthweight–cancer rela-
tion varied by age at diagnosis, we used a time-varying
coefficient approach, allowing for the estimation of
two HRs, one before a particular age at diagnosis and
one after. This time indicator variable is zero before the
relevant age and one afterwards. To test the sensitivity
of these results to changes in the indicator time vari-
able, we ran the analyses for 3, 4, 5, 6, and 7 years. The
results indicated that the HRs for birthweight were
significantly different before and after age 3 years,
then fairly stable for years 4 to 7 (data not shown). We
thus retained the cut-off at age 3 for our analysis.
To assess heterogeneity effects by cohort, we gener-
ated random-effects (shared frailty) Cox models. The
results were similar to those obtained using a strati-
fied analysis with each cohort serving as a stratum
that we report herein.
Analyses were conducted using Stata Statistical
Software, Version 12.1 (StataCorp, College Station, TX,
USA).
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Results
Table 1 presents the cohort-specific characteristics of
mothers, fathers, and index children. Mean maternal
age ranged from 23.6 [standard deviation (SD) 4.4]
years (TIHS) to 30.5 (SD 4.3) years (DNBC), with
paternal age showing similar variation. Scandinavian
mothers were the tallest, on average, yet maternal BMI
was fairly consistent across studies. Mean pregnancy
weight gain varied from 9.8 kg (4.80) (CPP) to 14.9
(5.8) kg (MoBa). Active maternal smoking during
pregnancy ranged from <10% (MoBa) to just over 50%
(TIHS). Mean birthweights were higher in the Scandi-
navian cohorts and lower in CPP.
Table S1 shows the distribution of cancer cases by
age and sex and the absolute risks of cancer in each
cohort. In total, the pooled analysis included 377
children with cancer, of whom 115 were diagnosed
with leukaemia, 98 with ALL, and 262 with non-
leukaemia-type cancers, with 54% of cancers occur-
ring among males. Ranges and mean ages at diagnosis
varied according to the length of cohort follow-up.
For each cohort, the HRs for all cancers, considering
birthweight as a continuous variable (per kilogram)
after controlling for GA and child’s sex consistently
exceeded 1.0 (Figure 1). Table 2 presents the pooled
analysis for birthweight and childhood cancer,
leukaemia, ALL, and non-leukaemia cancers. When
birthweight was considered as a continuous variable,
a significant increased risk of 26% for every kilogram
increment in birthweight was observed for all cancers,
after adjustment for GA and sex [HR 1.26 (95% CI
1.02, 1.54), P = 0.031]. Further adjustment for other
covariates (model 3) resulted in similar effect sizes. A
42% increase in risk was also observed for leukaemia,
adjusting for GA and child’s sex, with borderline sta-
tistical significance. HRs were elevated for children
born with birthweight ≥4.0 kg, compared with those
with lower birthweight for all cancer outcomes,
although the findings were not statistically significant.
The pattern was similar when comparing the highest
birthweight decile to the lower 90%, per cohort.
Figure 2 shows a monotonic increased risk of all
cancers with increasing birthweight [Spearman rank
correlation (rho) = 0.943, P = 0.005], as well as for leu-
kaemia and ALL, but not for non-leukaemia cancers,
in the pooled analysis.
The association between birthweight and childhood
cancer differed according to age at diagnosis (Table 3).
In models adjusted for GA and sex, a significant asso-
ciation between birthweight, using all metrics, was
observed for cancers occurring at or after age 3 years,
while HRs were reduced and not statistically signifi-
cant for younger children. This finding appeared to be
driven by non-leukaemia cancers. Although HRs were
higher for children diagnosed with leukaemia at or
after age 3 years, there was no statistical evidence of
time dependency.
Maternal pre-pregnancy BMI (unadjusted HR 1.01,
95% CI 0.99, 1.04) and pregnancy weight change
(unadjusted HR 1.0, 95% CI 0.99, 1.02) were not in
themselves associated with childhood cancer risks. We
explored potential effect modification by these
anthropometric measures on the association between
birthweight and the various cancer outcomes, and
found no significant interactions. Specifically, HRs, in
general, did not substantially differ when we exam-
ined the association between birthweight and cancer,
leukaemia or non-leukaemic tumours in two strata of
maternal pre-pregnancy BMI (top half of Table S2), or
in the high and low strata of gestational weight gain.
It should be noted that case numbers in each stratum
were relatively limited.
Comment
In this pooled analysis, we provide evidence from
prospectively collected data that birthweight, adjusted
for GA and sex, is positively associated with increased
cancer and leukaemia risks in children. In addition,
higher birthweight is particularly associated with non-
leukaemia cancer diagnosed at or after age 3 years.
1 kg increase, HR = 1.26 (1.02–1.54)
1 kg increase, HR = 1.20 (0.56–1.84)
1 kg increase, HR = 1.41 (0.91–1.92)
1 kg increase, HR = 1.75 (0.64–2.85)
1 kg increase, HR = 1.03 (0.72–1.34)
1 kg increase, HR = 1.51 (0.71–2.31)
1 kg increase, HR = 1.27 (0.31–2.23)
ALSPAC
CPP
DNBC
JPS
MoBa
TIHS
Pooled
0.5 1.0 1.5 2.0 2.5 3.0
Hazard ratio
Figure 1. Hazard ratios for any cancer in each cohort and
pooled overall for birthweight continuous (per kilogram
increase) in a Cox proportional hazards model adjusted for ges-
tational age and sex of child (model 2).
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Although maternal obesity is associated with high
birthweight,22,23 heightened cancer risks in high
birthweight offspring of overweight women or those
with excessive pregnancy weight gain were not
observed in our exploratory analyses.
For every kilogram increment in birthweight, the
HR for cancer was 1.26, similar to that reported in
large registry-based studies. The Norwegian Medical
Birth and Cancer Registries reported a HR of 1.23
(1.14–1.32)/kg birthweight increase adjusting for
GA,14 with no modification by age at diagnosis.
Recently, a case–control study9 (17 698 cases, 172 422
controls) based on registries in four Nordic countries
reported odds ratios (OR) of 1.2 and 1.4 for
birthweight 4000–4500 and 4500–6000 g, respectively,
for all cancers; OR estimates for ALL were also
similar to our pooled analysis, with little variation
among age groups.9 Comparable findings were
reported in a large cohort of ethnic Chinese in Singa-
pore.36 Among nearly 2 000 000 children identified
through the Danish Birth Registry, Westergaard
showed a Relative Risk (RR) for ALL of 1.46/kg
birthweight increase.37 In contrast, a recent large
study reporting on a total of 40 326 cases and 86 922
controls from the UK and US showed more modestly
elevated ORs of 1.06 per 500 g increment for all
cancer. For ALL, reported ORs were 1.08 (UK) and
1.11 (US), the latter adjusted for GA.11
Table 2. The association between birthweight and childhood cancers, leukaemia, ALL, and non-leukaemia cancers in the pooled
dataset
Birthweight metric (n
cases)
Model 1b Model 2c Model 3d
HRa 95% CI HRa 95% CI HRa 95% CI
Birthweight ≥4.0 kge
Cancer (377) 1.14 0.88, 1.48 1.19 0.91, 1.55 1.17 0.89, 1.54
Leukaemia (115) 1.25 0.80, 1.96 1.31 0.83, 2.08 1.21 0.74, 1.96
ALL (98) 1.21 0.74, 1.96 1.25 0.76, 2.06 1.21 0.72, 2.04
Non-leukaemia (262) 1.09 0.79, 1.50 1.14 0.82, 1.58 1.11 0.79, 1.56
Top 10% of birthweights in each cohortf
Cancer (377) 1.17 0.85, 1.61 1.22 0.88, 1.69 1.18 0.84, 1.65
Leukaemia (115) 1.25 0.72, 2.19 1.31 0.74, 2.31 1.16 0.63, 2.12
ALL (98) 1.14 0.61, 2.13 1.17 0.62, 2.23 1.08 0.55, 2.14
Non-leukaemia (262) 1.14 0.77, 1.68 1.18 0.80, 1.75 1.14 0.75, 1.71
Continuous birthweight, kgg
Cancer (377) 1.10 0.91, 1.31 1.26 1.02, 1.54 1.26 1.02, 1.56
Leukaemia (115) 1.25 0.89, 1.75 1.42 0.98, 2.06 1.35 0.90, 2.02
ALL (98) 1.16 0.81, 1.67 1.29 0.85, 1.93 1.29 0.83, 1.99
Non-leukaemia (262) 1.04 0.83, 1.28 1.19 0.93, 1.52 1.18 0.91, 1.54
aHazard ratios (95% CI) from a stratified Cox proportional hazard regression using all observations in the pooled dataset. In models 2
and 3 missing observations are imputed using a chained multiple imputation method.
bModel 1 is an unadjusted Cox proportional hazard regression model stratified by cohort in which birthweight is the only independent
variable.
cModel 2 is an adjusted Cox proportional hazard regression model stratified by cohort in which birthweight, gestational age, and sex of
the child are the independent variables.
dModel 3 is an adjusted Cox proportional hazard regression stratified by cohort in which, for:
• Cancer: birthweight hazard ratio is adjusted for gestational age, child’s sex, maternal age, paternal age (rescaled as quadratic), first
born, and maternal pre-pregnancy BMI.
• Leukaemia: birthweight hazard ratio is adjusted for gestational age, child’s sex, maternal age, total pregnancy weight gain, maternal
pre-pregnancy BMI, first born, and any maternal smoking during pregnancy.
• ALL: birthweight hazard ratio is adjusted for gestational age, child’s sex, paternal age (rescaled as quadratic), total pregnancy weight
gain, and any maternal smoking during pregnancy.
• Non-leukaemia cancers: birthweight hazard ratio is adjusted for gestational age, child’s sex, paternal age (rescaled as quadratic), total
pregnancy weight gain, first born, and maternal pre-pregnancy BMI.
eReference group for birthweight ≥4.0 kg is birthweight <4.0 kg.
fThe reference group for the top 10% of each cohort is the bottom 90% of each cohort.
gFor continuous birthweight, the hazard ratio represents a 1 kg increase in birthweight.
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In our dataset, high birthweight was strongly associ-
ated with non-leukaemia cancers diagnosed at or after
the age of 3 years. However, leukaemia risks were
not modified by age at diagnosis, echoing findings
from a large meta-analysis.5 The time-varying pattern
of birthweight effects may be due to the fact that
many cancer subtypes vary by age of onset and their
relation with birthweight may vary. As the I4C cohorts
mature, more detailed analyses on specific solid
tumours and lymphomas, including those which are
usually diagnosed in older children will be possible.
Few investigators have explored the effects of
maternal anthropometrics on the birthweight–
leukaemia or birthweight–cancer association.
McLaughlin and colleagues,26 in a case–cohort study,
noted an association between birthweight and leukae-
mia only among infants whose mothers weighed
<80 kg. That study lacked data on maternal height,
thus overweight per se, as measured by BMI, was not
addressed. They observed an effect of pregnancy
weight gain on ALL risk (RR 1.31), using a cut-off of
14.1 kg; however, no interaction with birthweight was
noted. Most women in the I4C cohorts were non-
obese, with pregnancy weight gain within the recom-
mended range. However, given worldwide trends in
maternal adiposity,38 this relation deserves further
scrutiny, particularly as our analysis was limited by
small numbers.
Moving beyond the established association between
accelerated foetal growth and childhood cancer to
explanatory mechanisms presents a considerable chal-
lenge. The complex contributions of both genetics and
the intrauterine environment are illustrated by early
observations, even among twins, that the heavier
sibling was more likely to develop leukaemia.3 Pro-
posed biological explanations include increased risks
of somatic mutations related to higher stem cell
number in large babies, and growth factor effects (e.g.
IGF) on both foetal growth and leukaemogenesis.
Early clues suggest that haplotypes in IGF1 and IGF2
are related to both high birthweight and ALL risk.39
Furthermore, overgrowth syndromes related to abnor-
mal methylation patterns of IGF genes have been asso-
ciated with particular cancers.40
Our study’s strengths include prospectively col-
lected data from a wide variety of geographic and
temporal settings. All birth and maternal characteris-
tics were ascertained at birth or during pregnancy,
minimising recall bias. Most of the contributing
cohorts were representative of their respective source
populations and cancer cases were derived from the
same populations as non-cases. This contrasts with
case–control studies, in which (because of low
response rates and consequent selection bias) controls
may differ substantially from the case population,
including in their birthweight distribution.41
Given that the correlation between birthweight and
birthweight-adjusted-for-GA is not high (kappa =
0.45),16 accounting for GA, as we did, is important. In
our analysis, adjustment for GA generally resulted in
improved precision of the HR estimates.
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Figure 2. Hazard ratios in the pooled dataset for birthweight* in
500 g increments in Cox proportional hazards models adjusted
for gestational age and sex of child (model 2) by cancer type.
(a) Cancer; (b) leukaemia; (c) acute lymphoblastic leukemia; (d)
non-leukaemia.
Spearman rank correlation for all cancers (rho) = 0.943, P =
0.005; for all leukaemia rho = 0.886, P = 0.019; for ALL rho =
0.943, P = 0.005, and for non-leukaemia cancers rho = 0.486,
P = 0.329.
*Birthweight 3.5–<4 kg is the reference category.
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The I4C platform enabled us to simultaneously
examine a wide range of potential confounders (e.g.
maternal adiposity, parity, diabetes, and maternal
active and passive smoking) unavailable in many pre-
vious record-linkage studies. However, the maximally
adjusted models did not differ substantially from
those which adjusted for child’s sex and GA.
Our study’s limitations include the modest number
of cases available for analysis – despite the pooling of
six cohorts. This restricted our ability to study sub-
types such as AML, as well as specific solid tumours,
and provided limited power to study interactions.
Missing covariate data necessitated imputation. Sub-
jects in some of the cohorts had not yet reached
15 years of age, so the entire childhood cancer experi-
ence of the cohort cannot be fully summarised.
Furthermore, methods of cancer ascertainment and
follow-up were inconsistent among the cohorts, and
for one cohort (TIHS), enrolment was selective.
Pooling data from different cohorts may be prob-
lematic due to heterogeneity of observed effects. For
instance, variation by ethnicity may occur in the asso-
ciation between IGF haplotypes, leukaemia, and
birthweight.41 Recent pooled analyses have shown
substantial heterogeneity in the association between
birthweight and cancer across countries.11,18 In an
attempt to diminish the effects of differential
birthweight distributions across cohorts, we stratified
all models by cohort and performed an analysis
taking into account the highest birthweight decile
within each cohort. The analysis using birthweight
(adjusted for GA and child sex) as a continuous
variable showed consistent results across cohorts
(Figure 1), and can serve as a simple measure facilitat-
ing comparison between large registry-based studies,
meta-analyses, and pooled analyses of case–control
studies.
In conclusion, evidence has now been added from
pooled prospectively collected data spanning six
countries on four continents over 50 years, strength-
ening the observation that increasing birthweight is a
risk factor for childhood cancer and leukaemia. Not-
withstanding the known association of maternal
obesity with high birthweight and potential metabolic
and cardiovascular morbidity, our preliminary find-
ings do not support a substantial main effect of mater-
nal adiposity on childhood cancer nor an interaction
with birthweight. With accumulating person-years of
follow-up, the addition of cancer cases from newer
cohorts, and the availability of biological samples,
I4C’s future pooled projects will enable further explo-
ration of the roles of pre- and postnatal events, genet-
ics and epigenetics, as well as providing power to
discern which cancer subtypes are associated with
high birthweight in older children. Further investiga-
tions should continue to focus on mechanisms and
exposures that jointly influence both foetal growth
and malignant transformation.
Table 3. Cancer, leukaemia, ALL, and non-leukaemia cancer hazard ratios in the pooled dataset using a time-varying coefficient for
birthweight across two time periods (age at diagnosis <3 vs. ≥3 years old) adjusting for sex and gestational age
Diagnosis Birthweight
Diagnosed <3 years old Diagnosed ≥3 years old Comparison of HRs
between time periods,
P-valueCases HR 95% CI Cases HR 95% CI
Cancer ≥4.0 kg 182 0.84 0.56 ,1.27 195 1.60 1.13, 2.26 0.018
Top 10% 0.80 0.46, 1.39 1.64 1.10, 2.44 0.037
Continuous 1.08 0.82, 1.42 1.44 1.11, 1.88 0.099
Leukaemia ≥4.0 kg 59 1.08 0.55, 2.13 56 1.56 0.84, 2.88 0.43
Top 10% 1.08 0.46, 2.54 1.55 0.72, 3.30 0.54
Continuous 1.29 0.79, 2.11 1.57 0.96, 2.57 0.56
ALL ≥4.0 kg 49 1.02 0.48, 2.15 49 1.49 0.77, 2.88 0.45
Top 10% 1.07 0.42, 2.73 1.28 0.54, 3.03 0.79
Continuous 1.23 0.72, 2.11 1.34 0.78, 2.30 0.81
Non-leukaemia ≥4.0 kg 123 0.75 0.45, 1.24 139 1.62 1.06, 2.46 0.020
Top 10% 0.67 0.33, 1.38 1.68 1.05, 2.68 0.035
Continuous 0.99 0.71 ,1.38 1.39 1.02 ,1.91 0.10
Model 2: Stratified Cox proportional hazard regression with a time-varying coefficient for birthweight based on an indicator function
for time defined at the age of diagnosis cut-point adjusted for gestational age and sex of the child.
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